Kari K. Alitalo
- University of Helsinki
Dr. Alitalo’s laboratory isolated and characterized the arterial endothelial tyrosine kinase Bmx, Tie1 angiopoietin receptor subunit and lymphangiogenic receptor VEGFR3, isolated the first lymphangiogenic growth factor, VEGF-C, and characterized VEGF-B as a growth factor for coronary and adipose vasculature. The laboratory demonstrated VEGF-C induced tumor lymphangiogenesis and metastasis, and inhibitors of the VEGFR-3 signal transduction pathway, which are in phase 2 clinical trials in age-related macular degeneration and diabetic macular edema, and developed growth factor therapy for lymphedema, which is now in phase 2 clinical trial. - A recent finding by his laboratory was the discovery of meningeal lymphatic vessels.
|Sep. 10 (Thu)
||Plenary Lecture 05
Translating Lymphangiogenesis Mechanisms to Therapeutics
||Translating Lymphangiogenesis Mechanisms to Therapeutics